Physician profile
Gregory Breen
NPI 1538119961
$28,640.79
in general payments reported to CMS, 2019-2025
42 companies · $25K in 2025
The $25K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $619 · 2021: $62.16 · 2022: $36.01 · 2023: $340 · 2024: $475 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $3,262 · Consulting Fee: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,150.00 |
| Food and Beverage | $3,262.25 |
| Consulting Fee | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21,448.45 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $1,540.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,298.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $858.77 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $404.21 | 2019-2025 | |
| Philips North America LLC | $306.85 | 2019-2025 | (5044) Mcot, Vest Therapy Und, (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.15 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $254.04 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $243.48 | 2019-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $190.71 | 2019-2025 | |
| Insmed, INC. | $135.19 | 2019-2025 | Arikayce |
| Harmony Biosciences LLC | $127.39 | 2020-2025 | Wakix |
| United Therapeutics Corporation | $126.50 | 2019-2025 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $108.27 | 2019-2020 | |
| Pulmonx Corporation | $104.49 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.